|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ѫ������ˮ�� |
|
C1��ø���Ƽ� |
|
������ |
|
���� |
| ��������������� | |
|
������ |
|
֣�� |
| PubMed | |
|
Article by JIANG Jian-xiong |
|
Article by ZHENG Min |
�Ŵ���Ѫ����ˮ���о���չ
������, ֣��
�㽭��ѧҽѧԺ�����ڶ�ҽԺƤ���� ���� 310009
�Ŵ���Ѫ����ˮ����һ������C1��ø���Ƽ��ĺϳ��ϰ�����ȱ�����µij�Ⱦɫ�������Ŵ������ò�������������,������о������䷢������Ҫ�����ǻ�����,�ʼ����ͷ�ø���Ƽ��ͻ�����2������������Ϊ��ҩ�з����ȵ�,Ϊ�����ṩ�˸����ѡ���Ŵ���Ѫ����ˮ�IJ��������ơ��ٴ����ּ����͡����ƽ��и�����
Advances in Hereditary Angioedema
Department of Dermatology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Department of Dermatology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Hereditary angioedema (HAE) is an autosomal dominant genetic disease caused by synthesis defect or dysfunction of C1 esterase inhibitor. Up to now, no satisfactory treatment is available for the disease, but recent studies indicate that the major mediator of angioedema is bradykinin, thus the plasma kallikrein inhibitor and the bradykinin 2 receptor (Bk2R) antagonist have become the hot spot of new drug investigation, and may provide clinicians with more therapeutic choices. The etiology, pathogenesis, clinical manifestations, as well as treatment of the disease are summarized.
[2] Bowen B,Hawk JJ,Sibunka S,et al.A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations.Clin Immunol,2001,98:157-163.
[3] Davis AE 3rd.The pathophysiology of hereditary angioedema.Clin Immunol,2005,114:3-9.
[4] Binkley KE,Davis AE 3rd.Estrogen-dependent inherited angioedema.Transfus Apher Sci,2003,29:215-219.
[5] Bork K,Siedlecki K,Bosch S,et al.Asphyxiation by laryngeal edema in patients with hereditary angioedema.Mayo Clin Proc,2000,75:349-354.
[6] Kranke B,Salmhofer W,Aberer W.Hereditary angioedema and normal C1-inhibitor activity in women.Lancet,2000,356:1440-1441.
[7] Binkley KE,Davis A 3rd.Clinical,biochemical,and genetic characterization of a novel estrogen-dependent inherited form of angioedema.J Allergy Clin Immunol,2000,106:546-550.
[8] Bork K,Dewald G.Hereditary angioedema type ��,angioedema associated with angiotensin �� receptor antagonists,and female sex.Am J Med,2004,116:644-645.
[9] Zuraw BL.Current and future therapy for hereditary angioedema.Clin Immunol,2005,114:10-16.
[10] Bork K,Barnstedt SE.Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema.J Am Dent Assoc,2003,134:1088-1094.
[11] Maeda S,Miyawaki T,Nomura S,et al.Management of oral surgery in patients with hereditary or acquired angioedemas:review and case report.Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2003,96:540-543.
[12] Bowen T,Cicardi M,Farkas H,et al.Canadian 2003 international consensus algorithm for the diagnosis,therapy,and management of hereditary angioedema.J Allergy Clin Immunol,2004,114:629-637.
[13] Bork K,Barnstedt SE.Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.Arch Intern Med,2001,161:714-718.
[14] De Serres J,Groner A,Lindner J.Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema:a review.jean.Transfus Apher Sci,2003,29:247-254.
[15] Ritchie BC.Protease inhibitors in the treatment of hereditary angioedema.Transfus Apher Sci,2003,29:259-267.
[16] Adis International Lmited.Icatibant:HOE 140,JE049,JE049.Drugs R D,2004,5:343-348.